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Chemotherapy (CT) and chemoradiotherapy (CTRT) both in neoadjuvant (neoadj) or adjuvant (adj) setting are associated with better overall 
survival (OS) over surgery alone in patients (pts) with resectable gastroesophageal (GE) adenocarcinoma (ADK). The best sequence and 
timing of treatments have still not been defined. A large cohort of GE ADKs derived from 2 high-volume Italian centers was analyzed to 
describe clinical outcomes and prognostic factors. 
Methods:
497 patients (pts) diagnosed with GE ADK who underwent surgery with curative intent from 2007 to 2016 were considered. Variables 
analyzed were: age, sex, tumor location, histology, T, N, M, R, G, HER-2, Helicobacter Pylori (HP) infection, (neo)adj CT, and adj CTRT. Analysis 
was performed according to ITT principle. 
Results:
Median age at diagnosis was 71 years (range 35-92). At 26.7 months (mo) median follow-up, median OS was 27.6 mo (range 1-127) and 
median time to recurrence (TTR) 10.8 mo (range 7.8-13.1). Adj CT was administered in 203 cases (41%); 116 pts (23%) had adj CTRT and 47 
(9%) neoadj CT. Statistically significant variables for OS and/or TTR at 12 months at univariate analysis were: age, T, N, M, R, G, adj CTRT, 
neoadj CT and adj CT. Results of multivariate analysis (MVA) are shown in Table 1. 
Conclusions:
Despite a short follow-up, our analysis performed on a very large cohort of consecutive pts confirms the prognostic value of T and N for both 
OS and TTR. Adj CT and CTRT had a significant impact on 1 year OS, while neoadj CT gave only a 12 months TTR significant benefit. Based on 
these results, perioperative treatment strategies should always be considered in the management of resectable GE cancer. 
1 MVA for OS and RFS
Variable
OS at 12 months
(p value)
TTR at 12 months
(p value)
T (4 vs 0-3) <0.001* 1.28 10 *
N (0 vs 1 vs 2 vs 3) <0.001* 3.91 10 *
M (0 vs 1) n.s. n.s.
R (0 vs 1 vs 2) 0.03* n.s.
G (3-4 vs 1-2) n.s. n.s.
Adj CTRT (no vs yes) 0.0028* n.s.
Neoadj CT (no vs yes) n.s. 0.0062*
Adj CT (no vs yes) 0.003* n.s.
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